Company intelligence / Profile preview
DelSite Biotechnologies, Inc.
Irving, Texas, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
The company developed a nasal powder vaccine platform (GelVac) and completed a Phase I safety study of GelVac nasal powder without an antigen. They received FDA approval to initiate a Phase I clinical study for GelVac nasal powder H5N1 influenza vaccine but filed for bankruptcy before proceeding further.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- PeptidesProteinsVaccines
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on DelSite Biotechnologies, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DelSite Biotechnologies, Inc..